This landmark investigation marks a critical milestone as the first randomized controlled trial (RCT) to probe the physiological and clinical ramifications of TRF on inflammatory bowel disease (IBD), specifically focusing on Crohn’s disease—a chronic, often debilitating inflammatory condition of the gastrointestinal tract. The research draws attention to the significant therapeutic potential embedded not simply in what patients consume, but crucially when they consume it, signaling an innovative paradigm shift in dietary management strategies for chronic inflammatory disorders.

The study enrolled 35 adult patients diagnosed with Crohn’s disease who also presented with obesity or overweight status. Subjects were randomly assigned to either the TRF intervention group, eating exclusively during an 8-hour daily interval, or to a control group adhering to their habitual diet with no imposed timing restrictions. Over the controlled 12-week period, researchers employed a comprehensive array of assessments, including clinical disease activity indices, systemic inflammatory biomarkers, and advanced body composition measurements using validated techniques.

Remarkably, participants adhering to the TRF schedule exhibited not only a significant reduction in Crohn’s disease activity but also experienced a meaningful decrease in visceral adiposity—a form of fat stored within the abdominal cavity closely linked to metabolic and immune dysfunction. The diminution of harmful fat deposits, often implicated in perpetuating inflammatory pathways, thus underscores the multifaceted benefits emerging from temporal modulation of food intake.

Biochemical analyses revealed that intermittent fasting led to substantial declines in circulating leptin and plasminogen activator inhibitor-1 (PAI-1), two molecules intimately involved in inflammatory processes and immune regulation. Leptin, widely recognized for its role in energy homeostasis, also functions as a pro-inflammatory adipokine, potentially exacerbating intestinal inflammation when elevated. PAI-1 is similarly implicated in inflammation and thrombosis, contributing to the complex immunopathology underlying Crohn’s disease. The downregulation of these biomarkers suggests that TRF exerts systemic anti-inflammatory effects that transcend mere weight loss or caloric restriction.

Indeed, the interventions were designed so that calorie intake and diet composition remained largely consistent between groups, highlighting that the timing of eating, rather than quantity or quality of food, likely drove the clinically significant outcomes. This distinction challenges traditional approaches focused exclusively on dietary composition and caloric limitation, redirecting scientific and clinical attention towards circadian biology and metabolic rhythm as pivotal factors in disease modulation.

The observed body weight changes further reinforce the potential metabolic benefits of TRF. While the fasting group lost approximately 5.5 pounds on average, the control cohort paradoxically gained around 3.7 pounds over the same interval. This differential weight trajectory aligns with the reduction in visceral fat and accompanying biochemical marker improvements, implying a synergistic interaction between circadian-aligned feeding regimens and metabolic health.

Lead investigator Dr. Natasha Haskey from the University of British Columbia accentuates the importance of these findings by framing time-restricted eating as a biologically grounded, sustainable lifestyle modification that equips patients with an empowering tool to enhance remission maintenance alongside pharmacotherapy. Her insights advocate for the integration of chrononutrition principles into comprehensive IBD management plans, particularly for patients seeking adjunctive, non-pharmacological interventions.

Senior author Dr. Maitreyi Raman highlights that TRF offers benefits that extend well beyond weight reduction, including meaningful symptomatic relief, metabolic recalibration, and promising alterations in the gut microbiome—the complex bacterial ecosystem intimately linked to immune homeostasis and intestinal health. Emerging evidence suggests that meal timing modulates microbial populations and their metabolites, which in turn influence mucosal inflammation and barrier function, forming a rationale basis for TRF’s therapeutic impact.

Despite the compelling outcomes, the authors emphasize the necessity for larger, long-term studies to validate the safety, efficacy, and mechanistic underpinnings of intermittent fasting in diverse Crohn’s disease populations. Variability in disease phenotype, medication regimens, and individual metabolic responses warrant careful consideration before broad adoption of TRF protocols in clinical practice.

The study was funded by the Crohn’s & Colitis Foundation under the Litwin IBD Pioneers program, reflecting an institutional commitment to pioneering research that places patients at the forefront of novel therapeutic discovery. Dr. Andres Lorenzo Hurtado, Senior Vice President of Translational Research & IBD Ventures at the Foundation, underscores the paradigm-shifting nature of this work, noting that strategic timing of nutrient intake can recalibrate immune function and metabolic health, opening new avenues for sustained remission.

These findings arrive at a critical time when the worldwide burden of IBD continues to rise, and existing treatment options often fall short of completely alleviating symptoms or halting disease progression. Time-restricted feeding represents a low-cost, patient-centered intervention with minimal side effects, potentially revolutionizing disease management by harnessing the inherent circadian regulation of metabolism and immune activity.

In conclusion, this pioneering clinical trial robustly establishes that intermittent fasting, through a disciplined 8-hour eating window, significantly ameliorates clinical disease activity and systemic inflammation in adults with Crohn’s disease and concurrent overweight or obesity. By intersecting the burgeoning fields of chronobiology, immunology, and gastroenterology, these results invite a re-examination of how dietary timing may fundamentally influence inflammatory diseases and represent a transformative step towards integrative therapies that enhance patient quality of life.

Subject of Research: People

Article Title: Time Restricted Feeding Reduces Body Mass Index, Visceral Adiposity, Systemic Inflammation, and Clinical Disease Activity in Adults with Crohn’s Disease: A randomized controlled study

News Publication Date: 9-Feb-2026

Web References:
10.1053/j.gastro.2025.11.008

References:
Published in Gastroenterology, 2026, DOI: 10.1053/j.gastro.2025.11.008

Keywords:
Inflammatory bowel diseases, Crohn’s disease, time-restricted feeding, intermittent fasting, systemic inflammation, visceral adiposity, chrononutrition, randomized controlled trial

This counterintuitive increase in cancer mortality during the RCT period invites careful scrutiny into the mechanistic pathways by which aspirin might influence tumor progression in older adults. Aspirin’s well-documented anti-inflammatory and antithrombotic properties have long made it a candidate for cancer prevention trials, premised on the theory that reducing systemic inflammation and platelet aggregation could impede cancer initiation or metastasis. Yet, these findings suggest a more complex interplay between aspirin and tumor biology in aging hosts, possibly involving differential effects on cancer progression rather than initiation.

Significantly, the elevated risk observed did not persist beyond the RCT timeframe, as the subsequent post-trial observational period showed no lingering legacy effects of aspirin on cancer mortality rates. This temporal limitation of increased risk underscores the importance of the treatment environment, dosage, and duration in modulating aspirin’s impact on cancer-related outcomes. It also raises essential questions regarding the optimal duration of aspirin intervention and the need for vigilant post-treatment monitoring in clinical settings.

The absence of a reduction in incident cancer incidence contradicts a body of prior research that posited aspirin’s chemopreventive potential, particularly in colorectal and other gastrointestinal malignancies. This discrepancy may stem from differences in study design, participant demographics, aspirin dosage, or the influence of confounding factors inherent in aging populations, such as comorbidities and polypharmacy. The older adult cohort in this study represents a critical demographic, given the increasing cancer burden and altered pharmacodynamics characterizing this age group.

Importantly, the methodology of this study leveraged randomized clinical trial protocols recognized for their robustness in minimizing selection bias and confounding variables. The RCT period offered controlled conditions under which the direct effects of aspirin could be isolated, while the post-RCT follow-up provided valuable observational insights into long-term outcomes. Such a bifurcated design enhances the validity of conclusions regarding aspirin’s effects on both cancer incidence and mortality.

From a clinical perspective, these findings prompt a reassessment of aspirin’s role in cancer prophylaxis among older adults, especially given the elevated mortality risk noted during active treatment. It suggests that clinicians should exercise caution when prescribing low-dose aspirin for cancer prevention in this population and weigh the potential risks against cardiovascular benefits. Detailed patient stratification based on individual risk profiles and coexisting conditions may be necessary to optimize therapeutic outcomes.

The study’s implications extend into the realm of molecular oncology and pharmacology, necessitating further investigation into the biological mechanisms underlying the increased cancer mortality risk associated with aspirin. Potential avenues include examining aspirin’s effects on immune modulation, tumor microenvironment alterations, and interactions with other medications commonly used by older adults. Advanced genomic and proteomic analyses could elucidate biomarkers predictive of adverse outcomes in aspirin-treated patients.

Furthermore, the lack of a sustained legacy effect post-RCT challenges assumptions about aspirin’s long-term influence on carcinogenesis. It suggests that any adverse impact may be confined to the period of active pharmacological intervention, emphasizing the dynamic nature of drug interactions with cancer biology over time. This temporal specificity is crucial for informing guidelines on the duration of aspirin therapy in cancer prevention trials.

The research also underscores the necessity for ongoing vigilance in the monitoring of cancer-related outcomes in clinical trials involving older adults. As the aging population grows, understanding the nuanced effects of commonly used medications like aspirin remains a priority in geriatric oncology. Enhanced post-trial surveillance protocols could facilitate early identification of adverse trends, enabling timely clinical interventions.

In summary, this rigorous investigation into low-dose aspirin use among elderly individuals reveals a dissociation between cancer incidence and mortality, highlighting a transient increase in cancer deaths confined to the randomized treatment phase without enduring effects beyond this interval. These findings call for a cautious interpretation of aspirin’s role in cancer prevention in older adults and advocate for personalized treatment approaches informed by ongoing research into the molecular determinants of aspirin’s dualistic impact.

This study marks a pivotal contribution to the broader discourse on cancer chemoprevention and drug safety in aging populations. It prompts a nuanced reevaluation of aspirin’s therapeutic profile and encourages the scientific community to refine clinical guidelines through targeted research. As researchers delve deeper into the mechanistic foundations of these observations, patient-centered strategies can evolve to mitigate risks while harnessing the potential benefits of low-dose aspirin and other agents in cancer-related care.

Subject of Research: The impact of low-dose aspirin on cancer incidence and mortality in older adults
Article Title: Not provided
News Publication Date: Not provided
Web References: Not provided
References: (doi:10.1001/jamaoncol.2025.6196)
Image Credits: Not provided

Keywords: Cancer, Mortality rates, Medications, Analgesics, Older adults, Oncology, Risk factors, Randomization, Clinical trials

Colorectal cancer remains a formidable global health challenge, annually affecting nearly two million individuals worldwide. Despite surgical removal of primary tumors, a significant proportion of patients—between 20 to 40 percent—experience metastatic disease, which complicates treatment and significantly worsens survival outcomes. Prior research hinted at aspirin’s protective effects against various cancers, but its efficacy had been inconsistent and largely anecdotal, especially when considering tumor molecular profiles. The ALASCCA trial, a meticulously designed multicenter study, now firmly establishes the benefits of aspirin in a subset of colorectal cancer patients defined by genetic markers.

Central to this study is the PIK3 signaling pathway, a molecular cascade integral to regulating diverse cellular processes including growth, survival, and proliferation. Mutations within genes of this pathway can unleash unchecked cellular division, a hallmark of oncogenesis. Approximately 40 percent of colorectal tumors possess such PIK3 alterations, thereby rendering them potential targets for pathway-directed therapies. The trial’s innovative approach stratified patients according to PIK3 mutation status, subsequently randomizing those with the mutation to receive either aspirin or placebo after surgery, followed over three years to assess recurrence rates.

The trial’s results were striking: patients harboring the PIK3 pathway mutation who received low-dose aspirin demonstrated a 55 percent reduction in cancer recurrence rates in comparison to the placebo group. This magnitude of clinical benefit is not only statistically significant but carries profound implications for long-term patient survival and quality of life. The reduction in recurrence risk underlines aspirin’s potential role not merely as a preventive agent but as an adjuvant therapeutic in genetically defined colorectal cancers.

Mechanistically, aspirin’s anti-cancer effect appears to be multifaceted. While traditionally recognized for its role as an anti-inflammatory drug and antiplatelet agent, aspirin is now understood to impact tumor biology directly. By mitigating inflammation, a recognized enabler of tumor progression, aspirin disrupts the inflammatory microenvironment that fosters cancer cell survival. Additionally, aspirin’s inhibition of platelet function impedes the ability of circulating tumor cells to evade immune detection and establish metastases. Furthermore, emerging evidence suggests aspirin may directly hinder tumor cell proliferation, collectively creating a hostile milieu for cancer persistence and spread.

Despite these compelling findings, the detailed molecular interplay through which aspirin mediates its anti-cancer effects remains incompletely understood. The study authors emphasize that the efficacy appears tightly linked to the genetic context within tumors, hinting at synergistic mechanisms predominantly operative in PIK3-altered cells. This highlights the paradigm shift toward precision oncology, where treatments are selected based on individual tumor genomic landscapes rather than broad clinical categories, thereby optimizing therapeutic efficacy and minimizing unnecessary exposure.

The ALASCCA trial’s design was robust and comprehensive, encompassing over 3,500 colorectal cancer patients recruited from 33 hospitals across Sweden, Norway, Denmark, and Finland. This geographic diversity enhances the generalizability of the findings across different populations. Importantly, the study was conducted with rigorous randomized controlled methods, the gold standard for clinical trials, minimizing biases and confounding variables, and thereby providing high-confidence evidence for clinical practice change.

Given aspirin’s extensive history as a readily available, cost-effective medication, its repurposing for colorectal cancer could dramatically reduce treatment costs and improve accessibility, especially in low-resource settings. Unlike many novel oncology drugs that carry prohibitive price tags and limited availability, aspirin’s global accessibility could potentially alleviate disparities in cancer care worldwide. The researchers underscore the importance of developing clinical guidelines incorporating genetic testing and tailored aspirin therapy to harness these benefits fully.

From a safety perspective, aspirin is well-characterized, with known side effects including gastrointestinal irritation and bleeding risks, particularly in individuals with pre-existing ulcers or bleeding disorders. These factors necessitate careful patient selection and monitoring when considering aspirin for adjuvant therapy in colorectal cancer. Nonetheless, its established safety profile and well-understood mechanism of action favor its adoption as a precision medicine tool, pending further validation and integration into clinical protocols.

The trial’s implications extend beyond colorectal cancer, suggesting a broader principle wherein common drugs may exhibit profound therapeutic potential when applied within genetically informed frameworks. Aspirin’s success in this context may pave the way for re-examining other traditional medications through the lens of tumor genomics, potentially unlocking new cancer therapies from existing pharmacopeias. This represents an exciting frontier in oncology research, blurring the lines between standard pharmacology and molecular medicine.

In conclusion, the ALASCCA trial marks a transformative milestone in colorectal cancer treatment, demonstrating that low-dose aspirin significantly reduces recurrence risk in patients with PIK3-mutated tumors. Spearheaded by Anna Martling and her team, the study not only confirms aspirin’s anti-cancer properties in a rigorous randomized setting but also exemplifies the power of integrating genetic insights into therapeutic strategies. As the oncology community embraces these findings, aspirin may become a cornerstone in personalized colorectal cancer management, heralding a new era of affordable, effective, and genetically tailored cancer care.

Subject of Research: People

Article Title: Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer

News Publication Date: 17-Sep-2025

Web References: DOI: 10.1056/NEJMoa2504650

Image Credits: Liza Simonsson

Keywords: Colorectal cancer, Colon cancer, Drug studies, Pharmacology

Cerebellar ataxias encompass a spectrum of disorders characterized primarily by disruptions in the fine coordination of voluntary movements, resulting from dysfunction or loss of neurons within the cerebellum and its connected circuits. These disturbances manifest as gait imbalance, impaired speech, and difficulties with hand-eye coordination. Given the progressive nature of these conditions and the current lack of definitive pharmacologic curative options, physical rehabilitation remains a cornerstone of symptomatic management. However, previous interventions focusing predominantly on balance exercises have shown variable efficacy, often limited by logistical challenges in accessing supervised therapy and the inability of patients to sustain gains over time.

The study employed a rigorous randomized controlled design involving participants diagnosed with various forms of cerebellar ataxias. Subjects were assigned to either a home-based, high-intensity aerobic exercise program or a dose-equivalent regimen emphasizing balance training. The aerobic regimen consisted of exercises designed to achieve and maintain elevated heart rates, promoting cardiovascular fitness while targeting neuromuscular control pathways. Intervention adherence was closely monitored through remote supervision and self-reporting tools, ensuring fidelity to the prescribed protocols.

Outcome measures included standardized ataxia rating scales, quantification of subjective fatigue using validated instruments, and objective assessments of aerobic capacity via cardiopulmonary exercise testing. At the conclusion of the intervention period, participants engaging in aerobic training exhibited significantly greater reductions in ataxia scores, indicating amelioration of motor coordination deficits. Moreover, fatigue severity, a common and debilitating symptom impacting quality of life, decreased substantially among these individuals. Aerobic capacity improvements confirmed the physiological impact of the training, underscoring the systemic benefits of sustained cardiovascular exertion in this population.

Importantly, the durability of the observed benefits was examined through a one-year follow-up. Participants who maintained regular aerobic exercises post-trial retained symptomatic improvements and enhanced aerobic fitness, indicating that continued engagement in high-intensity aerobic activity confers long-term advantages. This contrasts with previous rehabilitation paradigms wherein gains often diminish upon cessation of supervised therapy, emphasizing the necessity of interventions that are both effective and practicable for sustained implementation.

The underlying mechanisms by which aerobic exercise confers improvements in cerebellar dysfunction are multifaceted. Aerobic training may induce neuroplastic changes within cerebellar and extracerebellar networks, enhancing synaptic efficacy and promoting the preservation or recruitment of compensatory pathways. Additionally, systemic effects such as improved cerebral blood flow, modulation of inflammatory mediators, and increased neurotrophic factors likely contribute to neuroprotection and functional recovery. These biological processes align with emerging evidence supporting exercise as a potent neurorehabilitative modality in various neurodegenerative diseases.

Another critical consideration addressed by the study is the feasibility of delivering high-intensity aerobic training remotely, especially given the mobility restrictions faced by individuals with ataxia. The home-based intervention was structured to facilitate safe, guided exercise sessions without the need for frequent clinical visits, harnessing technology for monitoring and coaching. This approach has broad implications for expanding access to effective therapies, reducing healthcare burdens, and empowering patients to take active roles in managing their conditions.

While balance training remains a valuable component of ataxia rehabilitation, its comparative effectiveness was limited in this trial relative to aerobic exercise. The matched dosage ensured that differences in outcomes were attributable to the nature of the exercise rather than volume alone. This insight calls for a reevaluation of rehabilitation protocols, advocating for the incorporation of aerobic elements to optimize functional outcomes.

The study’s findings also underscore the importance of individualized exercise prescriptions tailored to patient capacity and disease severity. High-intensity aerobic training must be adapted to ensure safety and maximize adherence, highlighting the role of interdisciplinary teams including neurologists, physiotherapists, and exercise physiologists in designing and implementing comprehensive care plans.

Furthermore, this research sets a precedent for future clinical trials exploring multimodal interventions in cerebellar ataxias, encouraging the integration of neurological assessments with cardiovascular and metabolic health metrics. Expanding the evidence base with long-term, larger-scale studies will be crucial to validating and refining these preliminary findings.

In conclusion, this groundbreaking trial offers compelling evidence that home-based high-intensity aerobic exercise is a superior rehabilitative strategy for managing cerebellar ataxias compared to traditional balance training. By improving motor coordination, reducing fatigue, and enhancing aerobic fitness, this intervention addresses several key symptomatic domains, thereby elevating patient quality of life. The sustainability of benefits through continued training further reinforces its practical value. These results invite a paradigm shift in ataxia rehabilitation, promoting accessible, exercise-based therapies with the potential to alter disease trajectories.

The corresponding author for this pivotal study is Dr. Scott Barbuto, MD, PhD, who can be reached via email at sb3779@cumc.columbia.edu. The full research article, including comprehensive methodological details, author contributions, conflict of interest disclosures, and funding statements, is available in JAMA Neurology. This study was presented as a poster at the annual meeting of the American Neurological Association, highlighting its relevance and impact within the neurology community. Readers interested in the full text will be able to access it freely via an embargoed link provided at the time of publication.

Subject of Research: Therapeutic interventions for cerebellar ataxias through home-based exercise.

Article Title: [Not provided]

News Publication Date: [Not provided]

Web References: doi:10.1001/jamaneurol.2025.3421

Keywords: Cerebellar ataxia, Home care, Physical exercise, Clinical trials, Randomization, Symptomatology, Neurology

The findings of this investigation were published in the esteemed journal Annals of Internal Medicine, which underscores the study’s importance in the field of public health and cancer prevention. The researchers focused on an innovative approach where patient navigators—trained professionals who assist patients in navigating the healthcare system—played a pivotal role in guiding patients through the sometimes daunting process of scheduling and preparing for a colonoscopy after receiving abnormal test results. The statistics gathered during the study are both revealing and alarming, highlighting a significant gap between those who receive appropriate follow-up care and those who do not.

The study included a randomized clinical trial with a sample size of 970 patients ranging in age from 50 to 75 years. These individuals were identified based on having recent abnormal fecal immunochemical test (FIT) results—a screening method often used to detect potential colorectal issues. The potential risk posed by these abnormal results cannot be overstated, as timely follow-up with a colonoscopy can significantly reduce the risk of progression to colorectal cancer and improve outcomes.

Among the patients who received assistance from navigators, an impressive 55% followed through with their colonoscopy within one year. In contrast, only 42.5% of patients who did not have the support of a navigator completed the procedure. This 12% increase in completion rates highlights the effectiveness of utilizing navigators as active participants in the patient’s journey toward understanding and addressing their health issues. The results suggest that when patients are equipped with personalized assistance, they are more likely to engage with their health choices and manage potentially life-threatening conditions proactively.

Gloria Coronado, PhD, the first author of the paper and the associate director of population science at the University of Arizona Cancer Center, emphasized the critical importance of rapid follow-up after abnormal results. Coronado noted that promptly arranged colonoscopies can mitigate the risks of colorectal cancer, which can be deadly if not caught early. For patients who delay obtaining the necessary care, the consequences could be dire, with studies indicating that delayed follow-up can result in a sevenfold increase in mortality rates associated with colorectal cancer.

The investigational framework known as PRECISE (Predicting and Addressing Coloscopy Non-Adherence in Community Settings) adopted in the study, was implemented at Sea Mar Community Health Centers in Washington. This initiative highlighted how federally qualified health centers could pioneer effective methods to ensure they connect their patients with essential medical services. The patient navigators employed in this project made consistent efforts to communicate with participants, which included sending letters, making phone calls, and delivering timely text messages to ensure the patients understood the procedures and importance of their upcoming colonoscopy.

The holistic support provided by these navigators included comprehensive educational approaches focused on several key subject areas: identifying barriers to care, offering emotional and logistical support, preparing patients physically for the procedure, and following up post-procedure to evaluate both stress and satisfaction levels. The patient navigators’ commitment to these tasks not only simplified the patient’s experience but potentially saved lives by ensuring that necessary screenings were not overlooked.

The outcomes of this study point to a potentially effective model for cancer prevention strategies across diverse healthcare settings. Encouraging clinics to adopt similar navigation programs could facilitate a more standardized approach for informing patients of their health status and what further action is required. By integrating systematic patient navigation, clinics can foster a culture where patients are actively engaged in their health care decisions, thereby improving overall health outcomes.

The urgent need for such interventions reflects ongoing public health challenges faced by many communities. Enhanced survival rates from colorectal cancer are attainable if systems are put in place to ensure that patients understand their health information and the crucial steps they need to take afterward. The implications of this research extend beyond single clinics or health systems; they underscore the necessity for policy changes and increased funding towards patient navigation programs nationwide.

As the study continues to gain attention, it illustrates a clear message: empowering patients with information, support, and accessibility can fundamentally change their health trajectories. By removing barriers to care and addressing patients’ concerns holistically, we may move closer to reducing the alarming rates of colorectal cancer deaths. The path forward involves increasing awareness of the tools available to enhance patient involvement and reinforcing the adequacy of follow-up care.

Moving forward, the research team advocates for broader implementation of patient navigation as an essential part of care management for those receiving abnormal stool test results. They suggest that integrating these navigators into routine cancer screening processes can create a ripple effect of improved health outcomes in populations where accessibility and adherence to recommended follow-ups, like colonoscopies, remain critical concerns.

In conclusion, the findings of this enlightening study shine a spotlight on the effectiveness of patient navigators in motivating patients to follow through with crucial cancer screenings. As healthcare providers strive to enhance the overall well-being of their patients, it is imperative to take actionable steps in implementing supportive infrastructures that include navigational support for individuals facing challenging health decisions. The evidence presented here sets a precedent not only for colorectal cancer care but for future endeavors in improving public health practices linked to cancer prevention.

Subject of Research: People
Article Title: Patient Navigation to Improve Colonoscopy Completion After an Abnormal Stool Test Result
News Publication Date: April 1, 2025
Web References: Link to study
References: DOI: 10.7326/ANNALS-24-01885
Image Credits: Photo by Kris Hanning, U of A Health Sciences Office of Communications

Keywords: Colonoscopy, Colorectal cancer, Patient navigation, Fecal immunochemical test, Healthcare intervention, Public health, Cancer prevention, Health disparities, Clinical research, Follow-up care.